Mode
Text Size
Log in / Sign up
N/A Completed N=66 Treatment

A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China

Source: ClinicalTrials.gov NCT03710083 ↗
Enrolled (actual)
66
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Percentage of Guardian™ Sensor (3) Values That Are Within 20% Agreement of YSI — 93.2 percentage of paired readings

Summary

The purpose of this study is to demonstrate the performance and safety of the Guardian™ Sensor (3) over 170 hours (7 days) when inserted in the abdomen used in subjects age 14 - 75 years with the Guardian™ Connect System.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Guardian™ Sensor (3) Values That Are Within 20% Agreement of YSI
93.2
PRIMARY
Consensus Error Grid Analysis of Mean Rate of Paired Sensor Values and YSI Values in Zone A+B
100
PRIMARY
Clarke Error Grid Analysis of Mean Rate of Paired Sensor Values and YSI Values in Zone A+B
99.8
PRIMARY
Mean Absolute Relative Difference (MARD)
8.11

Eligibility Criteria

Inclusion Criteria

  • Subject is 14 - 75 years of age at time of screening
  • Subject has a clinical diagnosis of type 1 or 2 diabetes as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
  • Subject has adequate venous access as assessed by investigator or appropriate staff
  • Subject is willing to follow the study procedures and willing to come to study visits

Exclusion Criteria

  • Subject will not tolerate tape adhesive in the area of Guardian™ Sensor (3) placement as assessed by qualified individual.
  • Subject has any unresolved adverse skin condition in the area of study device or device placement (e.g., psoriasis, rash, Staphylococcus infection)
  • Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks
  • Subject is female and has a positive pregnancy screening test
  • Females of child bearing age and who are sexually active should be excluded if they are not using a form of contraception deemed reliable by investigator
  • Subject is female and plans to become pregnant during the course of the study
  • Subject has a hematocrit (Hct) lower than the normal reference range
  • Subject may not be on the research staff of those performing this study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03710083). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search